Allegro Ophthalmics
Pharmaceuticals, Rancho Viejo Rd, San Juan Capistrano, , 92675, California, 31473, United States, 1-10 Employees
Phone Number: +19*********
Who is ALLEGRO OPHTHALMICS
Allegro Ophthalmics, LLC is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class ...
Read More
-
Headquarters: 31473 Rancho Viejo Rd, San Juan Capistrano, California, 92675, United States
-
Date Founded: 2011
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Vicken Karageozian
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from ALLEGRO OPHTHALMICS
Allegro Ophthalmics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Allegro Ophthalmics
Answer: Allegro Ophthalmics's headquarters are located at Rancho Viejo Rd, San Juan Capistrano, , 92675, California, 31473, United States
Answer: Allegro Ophthalmics's phone number is +19*********
Answer: Allegro Ophthalmics's official website is https://allegroeye.com
Answer: Allegro Ophthalmics's revenue is $1 Million to $5 Million
Answer: Allegro Ophthalmics's SIC: 2836
Answer: Allegro Ophthalmics's NAICS: 541714
Answer: Allegro Ophthalmics has 1-10 employees
Answer: Allegro Ophthalmics is in Pharmaceuticals
Answer: Allegro Ophthalmics contact info: Phone number: +19********* Website: https://allegroeye.com
Answer: Allegro Ophthalmics, LLC is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class of drugs for the treatment of retinal diseases. Allegros lead investigational drug, risuteganib (Luminate), a broad-spectrum integrin inhibitor, downregulates oxidative stress upstream, at its source, simultaneously affecting all four pathways of oxidative stress that contribute to retinal diseases such as diabetic macular edema (DME) and nonexudative age-related macular degeneration (dry AMD). Risuteganib has successfully met the endpoints for three Phase 2 studies and is preparing to enter Phase 3 studies in DME during the first half of 2019. Allegro is working closely with the global retina community to bring to market new treatment options for leading causes of blindness and is committed to offering patients an improved quality of life sustained by self-sufficient, functional vision.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month